VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Both sexes                                         │ Both sexes                                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Mild to moderate tear film dysfunction clinical    │ Mild to moderate tear film dysfunction clinical    │     100 │
│ diagnose                                           │ diagnose                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Availability to go to each revision when indicated │ Availability to go to each revision when indicated │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with topical and/or systemic medication   │ Subjects with topical and/or systemic medication   │     100 │
│ or mechanical devices that interfere determinedly  │ or mechanical devices that interfere determinedly  │         │
│ on the results of the study (such as topical       │ on the results of the study (such as topical       │         │
│ immunomodulators, punctal plugs, corticosteroids,  │ immunomodulators, punctal plugs, corticosteroids,  │         │
│ preservative artificial tears, contact lenses)     │ preservative artificial tears, contact lenses)     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects (females) with active sexual life that do │ Subjects (females) with active sexual life that do │     100 │
│ not use a contraceptive method                     │ not use a contraceptive method                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female subjects who are pregnant or lactating      │ Female subjects who are pregnant or lactating      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female subjects with a positive urine pregnancy    │ Female subjects with a positive urine pregnancy    │     100 │
│ test                                               │ test                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who have participated on any other        │ Subjects who have participated on any other        │     100 │
│ research clinical trials on the last 40 days       │ research clinical trials on the last 40 days       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects legal or mentally disabled to give an     │ Subjects legal or mentally disabled to give an     │     100 │
│ informed consent for participating on this study   │ informed consent for participating on this study   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who can't comply with the appointments or │ Subjects who can't comply with the appointments or │     100 │
│ with every protocol requirement                    │ with every protocol requirement                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Non perforated corneal ulcer                       │ Non perforated corneal ulcer                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Perforated corneal ulcer                           │ Perforated corneal ulcer                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Autoimmune corneal ulcer                           │ Autoimmune corneal ulcer                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ocular surface scarring diseases                   │ Ocular surface scarring diseases                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ocular surface or annexes metaplastic lesions      │ Ocular surface or annexes metaplastic lesions      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Fibro vascular proliferation lesions on the        │ Fibro vascular proliferation lesions on the        │     100 │
│ conjunctival and/or corneal surface (i.e.:         │ conjunctival and/or corneal surface (i.e.:         │         │
│ pterygium)                                         │ pterygium)                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant chronic inflammatory diseases on any   │ Concomitant chronic inflammatory diseases on any   │     100 │
│ ocular structure                                   │ ocular structure                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute or infectious inflammatory disease           │ Acute or infectious inflammatory disease           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Corneal disease potentially requiring a treatment  │ Corneal disease potentially requiring a treatment  │     100 │
│ during the following 3 months                      │ during the following 3 months                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of topical or systemic drug products           │ Use of topical or systemic drug products           │     100 │
│ classified as forbidden                            │ classified as forbidden                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ocular surgical procedures 3 months before the     │ Ocular surgical procedures 3 months before the     │     100 │
│ protocol inclusion                                 │ protocol inclusion                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatments or procedures indicated on the tear     │ Treatments or procedures indicated on the tear     │     100 │
│ film dysfunction treatment, as punctal silicone    │ film dysfunction treatment, as punctal silicone    │         │
│ plugs                                              │ plugs                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Posterior segment diseases requiring a treatment   │ Posterior segment diseases requiring a treatment   │     100 │
│ or threatening the visual prognosis                │ or threatening the visual prognosis                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Retinal diseases potentially requiring treatment   │ Retinal diseases potentially requiring treatment   │     100 │
│ during the following 3 months                      │ during the following 3 months                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of penetrating keratoplasty                │ History of penetrating keratoplasty                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Soft or hard contact lenses use during the last    │ Soft or hard contact lenses use during the last    │     100 │
│ month from inclusion day                           │ month from inclusion day                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ \>18 to \< 90 years old                            │ >18 to < 90 years old                              │      95 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ TBUT \> 5 sec. and \< 10 sec                       │ TBUT > 5 sec. and < 10 sec                         │      96 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Schirmer: \> 4 mm and \< 14 mm                     │ Schirmer: > 4 mm and < 14 mm                       │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ OSDI \< 30 points                                  │ OSDI < 30 points                                   │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serious tear film dysfunction syndrome TBUT \< 5 s │ Serious tear film dysfunction syndrome TBUT < 5 s  │      98 │
│ Schirmer: \< 4 mm OSDI \> 30 pints Corneal         │ Schirmer: < 4 mm OSDI > 30 pints Corneal staining  │         │
│ staining \> grade III on the Oxford scale          │ > grade III on the Oxford scale                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Corneal staining \< grade III on the Oxford scale  │ Corneal staining < grade III on the Oxford scale   │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Positive drug addictions\* (verbal interrogatory)  │ Positive drug addictions* (verbal interrogatory)   │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                              │ CHIA Criteria                                     │   Score │
╞════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ Must have maximum age of 80 Years              │ Autoimmune corneal ulcer                          │      39 │
├────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ General Criteria                               │ Perforated corneal ulcer                          │      40 │
├────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years              │ Acute or infectious inflammatory disease          │      41 │
├────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Criteria related with ophthalmic ailments      │ Corneal disease potentially requiring a treatment │      45 │
│                                                │ during the following 3 months                     │         │
├────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Mild to moderate clinical stage of the disease │ Mild to moderate tear film dysfunction clinical   │      61 │
│                                                │ diagnose                                          │         │
╘════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 96
Average Levenshtein Ratio of individual lines: 92.28947368421052
OverAll Ratio: 94.14473684210526
